NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $344.15 million. The enterprise value is $360.82 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 29.85 million shares outstanding. The number of shares has increased by 11.80% in one year.
| Current Share Class | 29.85M |
| Shares Outstanding | 29.85M |
| Shares Change (YoY) | +11.80% |
| Shares Change (QoQ) | +2.05% |
| Owned by Insiders (%) | 4.07% |
| Owned by Institutions (%) | 30.84% |
| Float | 13.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.28 |
| Forward PS | 3.86 |
| PB Ratio | 34.95 |
| P/TBV Ratio | 35.03 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.59, with a Debt / Equity ratio of 7.48.
| Current Ratio | 5.59 |
| Quick Ratio | 4.63 |
| Debt / Equity | 7.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.61 |
Financial Efficiency
Return on equity (ROE) is -214.55% and return on invested capital (ROIC) is -16.83%.
| Return on Equity (ROE) | -214.55% |
| Return on Assets (ROA) | -14.74% |
| Return on Capital (ROIC) | -16.83% |
| Revenue Per Employee | $447,088 |
| Profits Per Employee | -$164,275 |
| Employee Count | 171 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 1.83 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.47% in the last 52 weeks. The beta is 2.06, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 2.06 |
| 52-Week Price Change | +16.47% |
| 50-Day Moving Average | 8.74 |
| 200-Day Moving Average | 8.98 |
| Relative Strength Index (RSI) | 61.64 |
| Average Volume (20 Days) | 78,993 |
Short Selling Information
The latest short interest is 249,421, so 0.84% of the outstanding shares have been sold short.
| Short Interest | 249,421 |
| Short Previous Month | 290,399 |
| Short % of Shares Out | 0.84% |
| Short % of Float | 1.91% |
| Short Ratio (days to cover) | 2.85 |
Income Statement
In the last 12 months, NeuroPace had revenue of $76.45 million and -$28.09 million in losses. Loss per share was -$0.99.
| Revenue | 76.45M |
| Gross Profit | 56.44M |
| Operating Income | -23.07M |
| Pretax Income | -31.51M |
| Net Income | -28.09M |
| EBITDA | -22.87M |
| EBIT | -23.07M |
| Loss Per Share | -$0.99 |
Full Income StatementBalance Sheet
The company has $56.83 million in cash and $73.50 million in debt, giving a net cash position of -$16.67 million or -$0.56 per share.
| Cash & Cash Equivalents | 56.83M |
| Total Debt | 73.50M |
| Net Cash | -16.67M |
| Net Cash Per Share | -$0.56 |
| Equity (Book Value) | 9.82M |
| Book Value Per Share | 0.33 |
| Working Capital | 67.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.49 million and capital expenditures -$299,000, giving a free cash flow of -$16.79 million.
| Operating Cash Flow | -16.49M |
| Capital Expenditures | -299,000 |
| Free Cash Flow | -16.79M |
| FCF Per Share | -$0.56 |
Full Cash Flow StatementMargins
Gross margin is 73.83%, with operating and profit margins of -30.17% and -36.74%.
| Gross Margin | 73.83% |
| Operating Margin | -30.17% |
| Pretax Margin | -36.74% |
| Profit Margin | -36.74% |
| EBITDA Margin | -29.91% |
| EBIT Margin | -30.17% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.80% |
| Shareholder Yield | -11.80% |
| Earnings Yield | -8.16% |
| FCF Yield | -4.88% |
Analyst Forecast
The average price target for NeuroPace is $15.29, which is 32.61% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.29 |
| Price Target Difference | 32.61% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 24.64% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -4.91 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.91 |
| Piotroski F-Score | 3 |